(Q51409558)

5 April 2018

title

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. (English)

1 reference

5 April 2018

1 reference

Stephanie Lheureux

1

1 reference

5 April 2018

Carolyn McCourt

2

1 reference

5 April 2018

B J Rimel

3

1 reference

5 April 2018

Linda Duska

4

1 reference

5 April 2018

Gini Fleming

5

1 reference

5 April 2018

Helen Mackay

6

1 reference

5 April 2018

David Mutch

7

1 reference

5 April 2018

Sarah M Temkin

8

1 reference

5 April 2018

Jean Lynn

9

1 reference

5 April 2018

Elise C Kohn

10

1 reference

5 April 2018

language of work or name

English

0 references

publication date

21 February 2018

1 reference

5 April 2018

published in

Gynecologic Oncology

1 reference

5 April 2018

Cancer drug discovery by repurposing: teaching new tricks to old dogs

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Compressing drug development timelines in oncology using phase '0' trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Window of opportunity studies: Do they fulfil our expectations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Biomarkers and surrogate end points--the challenge of statistical validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Hormonal therapy of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

HDAC as a therapeutic target for treatment of endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Epigenetic modification restores functional PR expression in endometrial cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Updates in therapy for uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Cell-cycle checkpoints and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.02.005

10.1016/J.YGYNO.2018.02.005

7 January 2021

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

29477660

1 reference

5 April 2018